Management of secondary progressive multiple sclerosis: Prophylactic treatment - Past, present, and future aspects

Paulus S. Rommer, Olaf Stüve

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Opinion statement: Whereas the number of treatment options in relapsing-remitting multiple sclerosis (RRMS) is growing constantly, alternatives are rare in the case of secondary-progressive multiple sclerosis (SPMS). Besides mitoxantrone in North America and Europe, interferon beta-1b and beta-1a are approved for treatment in Europe. Glucocorticosteroids, azathioprine, intravenous immunoglobulins (IVIG) and cyclophosphamide (CYC), although not approved, are commonly utilized in SPMS. Currently monoclonal antibodies (mab), and masitinib are under examination for treatment for SPMS. Hematopoietic stem cell transplantation and immunoablative stem cell transplantation are therapies with the aim of reconstitution of the immune system. This review gives information on the different therapeutics and the trials that tested them. Pathophysiological considerations are presented in view of efficacy of the therapeutics. In addition, therapeutics that showed no efficacy in trials or with unacceptable side effects are topics of this review.

Original languageEnglish (US)
Pages (from-to)241-258
Number of pages18
JournalCurrent Treatment Options in Neurology
Volume15
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Chronic Progressive Multiple Sclerosis
Therapeutics
Relapsing-Remitting Multiple Sclerosis
Mitoxantrone
Hematopoietic Stem Cell Transplantation
Intravenous Immunoglobulins
Azathioprine
Stem Cell Transplantation
Cell- and Tissue-Based Therapy
North America
Cyclophosphamide
Immune System
Monoclonal Antibodies

Keywords

  • Azathioprine
  • Cyclophosphamide
  • Daclizumab
  • Glucocorticosteroids
  • Interferon beta-1a
  • Interferon beta-1b
  • Intravenous immunoglobulins
  • Linomide
  • Management
  • Masitinib
  • Mitoxantrone
  • Prophylactic treatment
  • Rituximab
  • Secondary progressive multiple sclerosis
  • Treatment

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Management of secondary progressive multiple sclerosis : Prophylactic treatment - Past, present, and future aspects. / Rommer, Paulus S.; Stüve, Olaf.

In: Current Treatment Options in Neurology, Vol. 15, No. 3, 06.2013, p. 241-258.

Research output: Contribution to journalArticle

@article{c433daa84f1a4547bf8a98d7fc9cc7e1,
title = "Management of secondary progressive multiple sclerosis: Prophylactic treatment - Past, present, and future aspects",
abstract = "Opinion statement: Whereas the number of treatment options in relapsing-remitting multiple sclerosis (RRMS) is growing constantly, alternatives are rare in the case of secondary-progressive multiple sclerosis (SPMS). Besides mitoxantrone in North America and Europe, interferon beta-1b and beta-1a are approved for treatment in Europe. Glucocorticosteroids, azathioprine, intravenous immunoglobulins (IVIG) and cyclophosphamide (CYC), although not approved, are commonly utilized in SPMS. Currently monoclonal antibodies (mab), and masitinib are under examination for treatment for SPMS. Hematopoietic stem cell transplantation and immunoablative stem cell transplantation are therapies with the aim of reconstitution of the immune system. This review gives information on the different therapeutics and the trials that tested them. Pathophysiological considerations are presented in view of efficacy of the therapeutics. In addition, therapeutics that showed no efficacy in trials or with unacceptable side effects are topics of this review.",
keywords = "Azathioprine, Cyclophosphamide, Daclizumab, Glucocorticosteroids, Interferon beta-1a, Interferon beta-1b, Intravenous immunoglobulins, Linomide, Management, Masitinib, Mitoxantrone, Prophylactic treatment, Rituximab, Secondary progressive multiple sclerosis, Treatment",
author = "Rommer, {Paulus S.} and Olaf St{\"u}ve",
year = "2013",
month = "6",
doi = "10.1007/s11940-013-0233-x",
language = "English (US)",
volume = "15",
pages = "241--258",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Management of secondary progressive multiple sclerosis

T2 - Prophylactic treatment - Past, present, and future aspects

AU - Rommer, Paulus S.

AU - Stüve, Olaf

PY - 2013/6

Y1 - 2013/6

N2 - Opinion statement: Whereas the number of treatment options in relapsing-remitting multiple sclerosis (RRMS) is growing constantly, alternatives are rare in the case of secondary-progressive multiple sclerosis (SPMS). Besides mitoxantrone in North America and Europe, interferon beta-1b and beta-1a are approved for treatment in Europe. Glucocorticosteroids, azathioprine, intravenous immunoglobulins (IVIG) and cyclophosphamide (CYC), although not approved, are commonly utilized in SPMS. Currently monoclonal antibodies (mab), and masitinib are under examination for treatment for SPMS. Hematopoietic stem cell transplantation and immunoablative stem cell transplantation are therapies with the aim of reconstitution of the immune system. This review gives information on the different therapeutics and the trials that tested them. Pathophysiological considerations are presented in view of efficacy of the therapeutics. In addition, therapeutics that showed no efficacy in trials or with unacceptable side effects are topics of this review.

AB - Opinion statement: Whereas the number of treatment options in relapsing-remitting multiple sclerosis (RRMS) is growing constantly, alternatives are rare in the case of secondary-progressive multiple sclerosis (SPMS). Besides mitoxantrone in North America and Europe, interferon beta-1b and beta-1a are approved for treatment in Europe. Glucocorticosteroids, azathioprine, intravenous immunoglobulins (IVIG) and cyclophosphamide (CYC), although not approved, are commonly utilized in SPMS. Currently monoclonal antibodies (mab), and masitinib are under examination for treatment for SPMS. Hematopoietic stem cell transplantation and immunoablative stem cell transplantation are therapies with the aim of reconstitution of the immune system. This review gives information on the different therapeutics and the trials that tested them. Pathophysiological considerations are presented in view of efficacy of the therapeutics. In addition, therapeutics that showed no efficacy in trials or with unacceptable side effects are topics of this review.

KW - Azathioprine

KW - Cyclophosphamide

KW - Daclizumab

KW - Glucocorticosteroids

KW - Interferon beta-1a

KW - Interferon beta-1b

KW - Intravenous immunoglobulins

KW - Linomide

KW - Management

KW - Masitinib

KW - Mitoxantrone

KW - Prophylactic treatment

KW - Rituximab

KW - Secondary progressive multiple sclerosis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=84878321089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878321089&partnerID=8YFLogxK

U2 - 10.1007/s11940-013-0233-x

DO - 10.1007/s11940-013-0233-x

M3 - Article

C2 - 23609781

AN - SCOPUS:84878321089

VL - 15

SP - 241

EP - 258

JO - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 3

ER -